1. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. Issue 12 (15th October 2019) Authors: Astorgues-Xerri, Lucile; Vázquez, Ramiro; Odore, Elodie; Rezai, Keyvan; Kahatt, Carmen; Mackenzie, Sarah; Bekradda, Mohamed; Coudé, Marie-Magdelaine; Dombret, Herve; Gardin, Claude; Lokiec, Francois; Raymond, Eric; Noel, Kay; Cvitkovic, Esteban; Herait, Patrice; Bertoni, Francesco; Riveiro, María E. Journal: Leukemia & lymphoma Issue: Volume 60:Issue 12(2019) Page Start: 3067 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Issue 9 (30th July 2016) Authors: Berenguer‐Daizé, Caroline; Astorgues‐Xerri, Lucile; Odore, Elodie; Cayol, Mylène; Cvitkovic, Esteban; Noel, Kay; Bekradda, Mohamed; MacKenzie, Sarah; Rezai, Keyvan; Lokiec, François; Riveiro, Maria E.; Ouafik, L'Houcine Journal: International journal of cancer Issue: Volume 139:Issue 9(2016:Nov. 01) Page Start: 2047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗